文献速递其他结缔组织病

专家视角:系统性硬化症进展性肺纤维化的定义与管理

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2026-06-20

本文综述系统性硬化症相关间质性肺病(SSc-ILD)中进展性肺纤维化(PPF)的定义演变、预后决定因素与治疗格局。约20%至30%的SSc-ILD患者发生PPF,吗替麦考酚酯仍为一线首选,尼达尼布是唯一获批用于SSc-ILD和PPF的抗纤维化药物,联合治疗策略正在临床实践中获得关注。

要点

  • 约20%至30%的SSc-ILD患者会发展为PPF,可靠预测因素仍不明确。
  • 诊断时高分辨率CT筛查及定期肺功能监测对早期发现和及时管理至关重要。
  • 吗替麦考酚酯为一线首选,尼达尼布是唯一获批用于SSc-ILD和PPF的抗纤维化药。

核心结论

  • SSc-ILD病程高度异质,从惰性非进展型到快速进展性肺纤维化均可出现。
  • 识别进展风险患者仍是关键临床挑战,影像、功能评估和分子生物标志物有望改善风险分层。
  • 治疗已从传统免疫抑制向联合及抗纤维化策略演变。

研究设计与样本

  • 本文为综述,总结SSc-ILD中PPF的当前认识,聚焦定义演变、预后决定因素和治疗格局。

主要发现

  • SSc-ILD影响高达四分之三的SSc患者,是SSc发病和死亡的主要原因之一。
  • 约20%至30%的SSc-ILD患者发生PPF。
  • 尼达尼布是唯一获批用于SSc-ILD和PPF的抗纤维化药物,已显示减缓肺功能下降的疗效。
  • 吗替麦考酚酯仍为首选一线治疗。
  • 吗替麦考酚酯联合尼达尼布或利妥昔单抗、托珠单抗等生物制剂在临床实践中日益受关注,但比较数据有限。

关键数值与推荐

  • 诊断时常规高分辨率CT筛查及定期肺功能检测是早期发现和及时管理的关键。
  • 近期努力旨在统一纤维化性ILD中PPF的定义,认识到特发性肺纤维化之外存在共享的临床和病理生理机制。
  • 吗替麦考酚酯为 preferred first-line therapy。
  • 尼达尼布是唯一获批用于SSc-ILD和PPF的抗纤维化药物。

临床怎么用

  • 对SSc患者应在诊断时进行高分辨率CT筛查并定期监测肺功能以早期识别ILD。
  • 一线治疗可选吗替麦考酚酯,进展性纤维化患者可考虑尼达尼布。
  • 联合治疗(如吗替麦考酚酯联合尼达尼布或生物制剂)可在临床实践中考虑,但需注意比较数据有限。

局限性

  • 可靠预测SSc-ILD进展的因素仍不明确。
  • 联合治疗的比较数据有限。
  • 个性化、循证管理仍存在未满足需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three-quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF). Identifying patients at risk for progression remains a key clinical challenge. Routine screening with high-resolution computed tomography at diagnosis and regular pulmonary function test monitoring are essential for early detection and timely management. Recent efforts have sought to harmonize the definition of PPF across fibrosing ILDs, recognizing shared clinical and pathophysiological mechanisms beyond idiopathic pulmonary fibrosis. Approximately 20% to 30% of patients with SSc-ILD develop PPF, yet reliable predictors of progression remain elusive. Advances in imaging, functional assessment, and molecular biomarkers hold promise for improving risk stratification. Therapeutic approaches have evolved from conventional immunosuppression toward combination and antifibrotic strategies. Mycophenolate mofetil remains the preferred first-line therapy, whereas nintedanib is the only antifibrotic agent approved for both SSc-ILD and PPF, having demonstrated efficacy in slowing lung function decline. Combination therapy, particularly mycophenolate mofetil with nintedanib or biologics such as rituximab and tocilizumab, is gaining traction in clinical practice despite limited comparative data. Emerging antifibrotic and anti-inflammatory agents offer new therapeutic prospects. This review summarizes current understanding of PPF in SSc-ILD, focusing on its evolving definition, prognostic determinants, and treatment landscape, and highlights unmet needs for personalized, evidence-based management.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Benfaremo D, Khanna D, Campochiaro C, et al. Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis. Arthritis Rheumatol. 2026. PMID: 42223210. doi:10.1002/art.70237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。